



05.21-04

IPW

EXPRESS MAIL CERTIFICATE

Express Mail" mailing label number : EL 984 914 472 US

Date of Deposit : May 20, 2004

Type of Documents : Information Disclosure Statement;
Form 1449 (3 pages);
Cited References / two (2); and
Return Postcard

Serial No. : 10/692,105

Filing Date : October 23, 2003

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Diane Marshall (signature)
Diane Marshall



PATENTS
EL 984 914 472 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Bradley, *et al.* : Examiner: To be assigned
Serial No.: 10/692,105 : Art Unit: 1654
Filed: October 23, 2003 : Docket No.: B185 1015.1
For: **Process for the Production of a**
Reversibly Inactive Acidified Plasmin
Composition :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the references listed on the attached Form PTO-1449 to the Commissioner for Patents. This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits of the application. Accordingly, it is believed that no fees are due. However, should any fees be due, the Patent Office is hereby authorized to charge Deposit Account No. **09-0528**.

Also, in addition to the references listed on Form PTO-1449, Applicants wish to call the Examiner's attention to copending U.S. Appln. No. 10/143,156; 10/143,112; 10/143,157; and 10/280,444. These applications and the above-captioned application claim priority to original parent Appln. No. 09/438,331 (now U.S. Patent No. 6,355,243).

Copies of two references (F1 and D24) are provided herewith. Applicants have not provided copies of the remaining references in this submission because the remaining references are either U.S. patent documents or are believed to be available in the file of patent

Appln. No. 10/143,156. However, applicants will provide copies of any references should they be requested by the Examiner.

Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that an exhaustive search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of the information, and to form independent opinions as to their significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.


Date: May 20, 2004



Carl B. Massey, Jr.
Attorney for Applicants
Registration No. 44,224

Docket: **B185 1015.1 (MSC 8009.5)**

Womble Carlyle Sandridge & Rice, PLLC
Post Office Box 7037
Atlanta, Georgia 30357-00378
Telephone (336) 721-3681
Facsimile(336) 726-8074



FORM 1449-1449

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.
B185 1015.1

Serial No.
10/692,105

Applicant
Bradley, *et al.*

Filing Date
October 23, 2003

Group
1654

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	P1	6,479,253	11/2002	Silver, <i>et al.</i>			
	P2	6,139,819	10/31/00	Unger, <i>et al.</i>			
	P3	5,879,923	3/9/99	Yago, <i>et al.</i>			
	P4	5,776,452	7/7/98	Eibl, <i>et al.</i>			
	P5	5,767,269	6/1998	Hirsh, <i>et al.</i>			
	P6	5,728,674	1998	Sprecher, <i>et al.</i>			
	P7	5,472,692	12/5/95	Liu, <i>et al.</i>			
	P8	5,407,673	1995	Reich, <i>et al.</i>			
	P9	5,328,996	7/1994	Boyle			
	P10	5,304,383	4/19/94	Eibl, <i>et al.</i>			
	P11	5,290,692	3/1994	Suzuki, <i>et al.</i>			
	P12	5,288,489	2/1994	Reich, <i>et al.</i>			
	P13	5,165,912	11/1992	Selmer, <i>et al.</i>			
	P14	5,024,829	6/1991	Berger, <i>et al.</i>			
	P15	4,908,204	3/1990	Robinson, <i>et al.</i>			
	P16	4,774,087	9/1988	Wu, <i>et al.</i>			
	P17	4,663,146	5/1987	Morser, <i>et al.</i>			
	P18	4,462,980	7/1984	Diedrichsen, <i>et al.</i>			
	P19	4,446,316	5/1984	Chazov, <i>et al.</i>			
	P20	4,442,213	4/1984	Heber, <i>et al.</i>			
	P21	4,361,653	11/1982	Watanabe, <i>et al.</i>			
	P22	4,361,652	11/1982	Uemura, <i>et al.</i>			
	P23	4,177,262	12/1979	Lormeau, <i>et al.</i>			
	P24	4,082,612	04/1978	Robbins, <i>et al.</i>			
	P25	3,950,513	04/1976	Jensen			
	P26	3,434,929	03/1969	Buck. <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	F1	EP 0256836 A1	08/87	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	D1	Ambrus, C., <i>et al.</i> , "Insolubilized Activators of the Fibrinolysis System," <i>J. Med.</i> 3: 270-281 (1972).
	D2	Ambrus, J.L., <i>et al.</i> , "Clinical Pharmacology of various types of fibrinolytic enzyme preparations," <i>Am. J. Cardiol.</i> , 6:462-475 (1960).
	D3	Amris, C.J., <i>et al.</i> , "Effect of Plasmin Therapy on Blood Coagulation and on Plasma Proteins in Patients with Cancer," <i>Danish Medical Bulletin</i> , 11(5): 141-145 (1964).
	D4	Amris, C.J., <i>et al.</i> , "Turnover and Distribution of ¹³¹ I-Labelled Procine Plasmin in Man and Dog," <i>Danish Medical Bulletin</i> , 11(5): 146-152 (1964).
	D5	Anlyan, W., <i>et al.</i> , "Experiences with Fibrinolysis in Peripheral Vascular Occlusive Disease," <i>Am. J. Cardiol.</i> , 6: 507-512 (1960).
	D6	Barrett, A.J., <i>et al.</i> , "The Electrophoretically 'Slow' and 'Fast' Forms of the α 2-Macroglobulin Molecule," <i>Biochem. J.</i> , 181: 401-418 (1979).
	D7	Boucek, R., <i>et al.</i> , "Segmental Perfusion of the Coronary Arteries with Fibrinolysis in Man Following a Myocardial Infarction," <i>Am. J. Cardiol.</i> , 6: 525-533 (1960).
	D8	Boyles, P.W., <i>et al.</i> , "Comparative effectiveness of intravenous and intra-arterial fibrinolysis therapy," <i>Am. J. Cardiol.</i> , 6: 439-446 (1960).
	D9	Castellino, F.J. and J.R. Powell, "Human Plasminogen," <i>Meth. Enzymology</i> , 80: 365-378 (1981).
	D10	Collen, D., <i>et al.</i> , "Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration," <i>J. of Clin. Invest.</i> , 71(2): 368-376 (1983).
	D11	Deutsch, D.G. and E.T. Mertz, "Plasminogen: purification from human plasma by affinity chromatography," <i>Science</i> 170: 1095-1096 (1970).
	D12	Freitag, H., <i>et al.</i> , "Lys-plasminogen as an Adjunct to Local Intra-arterial Fibrinolysis of Carotid Territory Stroke: Laboratory and Clinical Findings," <i>Neuroradiology</i> , 38: 181-185 (1996).
	D13	Hedner, U., <i>et al.</i> , "Effects of Porcine Plasmin on the Coagulation and Fibrinolytic Systems in Humans," <i>Blood</i> , 51(1): 157-164 (1978).
	D14	Kitamoto, Y., <i>et al.</i> , "A Femoral Vein Catheter with Immobilized Urokinase (UKFC) as an Antithrombotic Blood Access," <i>Trans. Am. Soc. Artif. Intern. Organs</i> , 33: 136-139 (1987).
	D15	Larsen, V., "Fibrinolytic Enzyme in the Treatment of Patients with Cancer," <i>Danish Medical Bulletin</i> , 2(5): 137-140 (1964).
	D16	Larson, V., <i>et al.</i> , "Fibrinolytic Treatment with Activator-Free Porcine Plasmin," <i>Scand. J. Clin. Invest.</i> 18(Suppl. 89): 34-73 (1966).
	D17	Lijnen, H.R., <i>et al.</i> , "Activation of plasminogen by pro-urokinase," <i>J. Biol. Chem.</i> , 261(1): 1253-1258 (1986).
	D18	Lippschutz, E.L., <i>et al.</i> , "Controlled study of the treatment of coronary occlusion with urokinase-activated human plasmin," <i>Am. J. Cardiol.</i> , 16:93-98 (1965).

	D19	Moser, K., "Effects of Intravenous Administration of Fibrinolysin (Plasmin) in Man," <i>Circulation</i> , 20: 42-55 (1959).
	D20	Mizutani <i>et al.</i> "Potential thrombolysis under selective infusion of autolotous plasmin (AP) solution," <i>Japanese Heart Journal</i> , 30(5): 723-732 (1989).
	D21	Nilsson, T. and B. Wiman, "On the structure of the stable complex between plasmin and alpha-2-antiplasmin," <i>FEBS Lett.</i> , 142(1): 111-114 (1982).
	D22	Novokhatny, V. <i>et al.</i> "Thrombolytic potential of locally delivered active plasmin (Pm): In vitro assessment and in vivo comparison with tPA in the rabbit jugular vein thrombosis model," <i>Blood, J. of the Am. Soc. of Hematology</i> , 92(10) Suppl. 2, Abstract 3400. (Nov. 15, 1998).
	D23	Robbins, K.C. and L. Summaria, "Plasminogen and Plasmin," <i>Meth. Enzymol.</i> 45: 257-273 (1976).
	D24	Robbins, K.C., <i>et al.</i> , "Purification of human plasminogen and plasmin by gel filtration on Sephadex and chromatography on Diethylaminoethyl-Sephadex, <i>The Journal of Biological Chemistry</i> , 238(3): 952-962 (1963).
	D25	Sherry, S., "The Origin of Thrombolytic Therapy," <i>J. Am. Coll. Cardiol.</i> , 14(4): 1085-1092 (1989).
	D26	Verstraete, M., "The Fibrinolytic System: from Petri Dishes to Genetic Engineering," <i>Thrombosis and Haemostasis</i> , 74(1): 25-35 (1995).
	D27	Wiman, B., "Affinity-chromatographic purification of human alpha 2-antiplasmin," <i>Biochem. J.</i> , 191(1): 229-232 (1980).

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE:	DATE CONSIDERED: